XLV: Congress Is Buying the Boring Sector Again — Maybe You Should Too

# XLV: Congress Is Buying the Boring Sector Again — Maybe You Should Too

Here's a fun fact to ruin your next dinner party: while everyone's been busy arguing about whether AI capex is a bubble, the sleepiest, most unsexy corner of the S&P 500 quietly beat the index by nearly two-to-one in a single week this summer. XLV gained 3.2% in the week ending June 19 while the broader market managed 1.8%. Healthcare — the sector your uncle owns because his advisor told him to and then forgets about — just had a moment. And a few people in Washington apparently noticed before the rest of us did.

Let's start with the setup, because it's genuinely more interesting than "defensive sector does defensive sector things." XLV is riding two horses at once right now. One is the classic flight-to-safety trade — money moving into stable, cash-generative healthcare names as the market wobbles at all-time highs. The other is a genuine growth story: rate-cut expectations are accelerating, which is rocket fuel for a sector full of long-duration cash flows and dividend yields that suddenly look a lot more attractive when the risk-free rate is falling. That's a rare combination — defense that doesn't require you to sacrifice offense. Add in a 25% year-to-date surge from Johnson & Johnson on the back of an FDA approval, and a trade deal that capped pharma import tariffs at 15% (removing an overhang that battered the sector all through 2025), and you've got a legitimate multi-catalyst bull case, not just a "stocks go up when people are scared" story.

Now, the Congress angle. I don't love leading with this because it always sounds like conspiracy-brain, but the numbers are the numbers: 16 members of Congress have disclosed 34 trades in XLV, and from 2015 to 2025 it's been 8 buys against a single sell among six lawmakers. Net buyers, consistently, for a decade. Disclosed buys are running 4.8% ahead of the last quoted price. Maybe it's coincidence that the people who write drug pricing legislation and sit on committees with FDA oversight keep accumulating a healthcare ETF right before tariff relief and approval news breaks. Maybe it's not. Either way, it's a data point worth filing under "smart money defensive positioning," and it lines up neatly with the fundamental story rather than contradicting it.

Here's where I get less enthusiastic. XLV was still down roughly 3% year-to-date even after that hot June, despite a 14% trailing-12-month gain — which tells you this rally is a comeback story, not a breakout. The sector's spent most of 2026 playing catch-up to a market that's been partying without it. And the fund's fate is uncomfortably tethered to a handful of names — Eli Lilly's GLP-1 franchise being the big one. If a competitor drug shows up, or if Washington finally gets serious about drug pricing reform (a risk that never actually goes away, tariff relief notwithstanding), XLV doesn't just wobble, it takes a real hit.

The technicals add a note of caution to an otherwise clean story. RSI north of 67 is flashing overbought, price is running well above both its 20- and 50-day averages, and it's sitting right up against 52-week-high resistance near $168.50. That trailing P/E of 30 isn't screaming "cheap defensive rotation trade" anymore — it's screaming "everyone already showed up to this party." Meanwhile Benzinga's been flagging money rotating into staples and financials instead, and UnitedHealth's recent pullback is a reminder that "diversified healthcare exposure" doesn't mean immune to single-name pain.

So where does that leave us? XLV at 0.08% expense ratio is still the cheapest, cleanest way to own this trade — cheaper than IYH, broader than betting on PPH's steeper-fee, narrower exposure. The bull case (rate cuts, tariff relief, FDA tailwinds, quiet Congressional accumulation) is real. But you're buying it after a sprint, not before one, with resistance dead ahead and a GLP-1-sized single point of failure lurking underneath the index weighting.

My take: this isn't a "back up the truck" moment, it's a "own it, don't chase it" moment. Let it pull back toward the mid-$150s to $160s before adding, and treat a clean break above $168.53 as confirmation rather than an invitation to FOMO in. Boring sectors don't need to be bought exciting.